The specific aims of the project are to synthesize new chemical compounds and evaluate them for anticonvulsant activity. The long-term objectives include the discovery of new classes of anticonvulsant agents and the development of better anticonvulsant compounds which will lack the adverse effects of currently used antiepileptic agents. Hitherto, no chemical entity, nor surgical intervention has offered a complete cure for all types of epilepsy. The research plan is designed to exploit, in a systematic manner two interesting, and hitherto unique, lead moieties developed in our laboratories: the cyclic enaminones; and the spiroimidooxy analogs. The experimental design comprises the synthesis of new compounds of each moiety, by procedures previously reported in our laboratory, with appropriate modifications. In addition, molecular modeling techniques will be employed and the Free-Wilson analysis, as detailed by P.N. Craig(1,2) will be used in the development of quantitative structure activity relationships for each moiety. Regression analysis equations will be developed to provide clarification on the roles of chirality, lipophilicity (pi), electronic (alpha) character of the substituents, dipole moment (mu), steric parameters (Es), and molar volume (Ut) exercise on anticonvulsant activity. The application of energy minimization (MM2 and MM3) as well as molecular dynamics analysis will also be used to determine the lowest energy conformer of each compound and compared to both phenytoin, and carbamazepine, each minimized, to assess root-mean-square (rms) deviation of the superimposed molecules. X-ray structure analysis, sodium channel binding analysis, and corneal and amygdala kindling data of the active compounds will be performed in collaborating laboratories.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Popa, Laurentiu S; Hewitt, Angela L; Ebner, Timothy J (2013) Purkinje cell simple spike discharge encodes error signals consistent with a forward internal model. Cerebellum 12:331-3
Fuller, T L; Canada, R G (1999) Enhancement of cisplatin cytotoxicity by terbium in cisplatin-resistant MDA/CH human breast cancer cells. Cancer Chemother Pharmacol 44:249-52
Canada, R G; Paltoo, D N (1998) Binding of terbium and cisplatin to C13* human ovarian cancer cells using time-resolved terbium luminescence. Biochim Biophys Acta 1448:85-98
Paltoo, D N; Canada, R G (1998) Effects of terbium on the cytotoxicity of cisplatin in FaDu human head and neck squamous cell carcinoma. Cancer Biochem Biophys 16:213-27
Ting, P; Cushenberry, P A; Friedman, T C et al. (1997) Enhanced brain opioid receptor activity precedes blood-brain barrier disruption. Acta Neurochir Suppl 70:250-3
Mack, K M; Canada, R G; Andrews, P A (1997) The effects of terbium on the cellular accumulation of cisplatin in MDA-MB-231 human breast tumor cells. Cancer Chemother Pharmacol 39:217-22
Dennis, G C; Dehkordi, O; Millis, R M et al. (1996) Monitoring of median nerve somatosensory evoked potentials during cervical spinal cord decompression. J Clin Neurophysiol 13:51-9
Canada, R G; Andrews, P A; Mack, K M et al. (1995) The effects of terbium on the accumulation of cisplatin in human ovarian cancer cells. Biochim Biophys Acta 1267:25-30
Ting, P; Xu, S; Krumins, S (1994) Endogenous opioid system activity following temporary focal cerebral ischemia. Acta Neurochir Suppl (Wien) 60:253-6
Canada, R G (1993) Calcium receptor binding of cisplatin and terbium in human breast tumor cells after hyperthermia. Radiat Res 133:170-5